Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Find out what a historical investment in RAPPORT THERAPEUTICS INC. would be worth today using our RAPP stock calculator.
Buying RAPP shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in RAPPORT THERAPEUTICS INC. in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in RAPP
What is the ticker symbol of RAPPORT THERAPEUTICS INC.?
The ticker symbol for RAPPORT THERAPEUTICS INC. is RAPP.
How much is one share of RAPP?
One share of RAPP is valued at $23.59 as of 20 November 2026.
What is the market capitalisation of RAPPORT THERAPEUTICS INC. RAPP?
As of 20 November 2026 RAPPORT THERAPEUTICS INC. has a market cap of $1.39B.
What is the 52-week high for RAPPORT THERAPEUTICS INC. stock?
The RAPPORT THERAPEUTICS INC. 52-week high stock price is $52.93.
What is the 52-week low for RAPPORT THERAPEUTICS INC. stock?
The RAPPORT THERAPEUTICS INC. 52-week low stock price is $22.06.
Can I buy RAPP shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy RAPP shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in RAPP on Stake
Buy RAPP from US$3 brokerage
Invest in 11,000+ U.S. stocks and ETFs
Own a slice of RAPP from only US$10 with fractional shares